Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1761 - The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study


08 Oct 2016


Poster Display


Neill Iscoe


Annals of Oncology (2016) 27 (6): 411-415. 10.1093/annonc/mdw382


N. Iscoe1, R. Govindan2, A.M. Hossain3, B. San Antonio4, N. Chouaki5, M. Koczywas6, E. Vokes7, S. Senan8

Author affiliations

  • 1 Global Medical Affairs, Eli Lilly and Company, M1N 2E8 - Toronto/CA
  • 2 Division Of Oncology, Washington University School of Medicine, St. Louis/US
  • 3 Statistics, Eli Lilly and Company, Indianapolis/US
  • 4 Medical, Eli Lilly and Company, Madrid/ES
  • 5 Oncology, Eli Lilly and Company, Neuilly sur Seine/FR
  • 6 Medical Oncology & Therapeutic Research, City of Hope, Duarte/US
  • 7 Hematology/oncology, The University of Chicago Medical Centre, Chicago/US
  • 8 Radiotherapy Oncology, Vrije University Medical Centre (VUMC), Amsterdam/NL


Abstract 1761


Real-world evidence of the significant impact of PET staging on survival outcomes because of stage migration (upstaging) has been previously documented. However, the effect of stage migration as a result of PET has rarely been measured in randomized trials in the locally advanced (stage IIIA/B) setting. Here, we report the results from post-hoc subgroup analyses based on PET scan use in non-small cell lung cancer (NSCLC) patients in the PROCLAIM study.


The intent-to-treat (ITT) population of 598 patients with stage IIIA/B nonsquamous NSCLC were randomized to either pemetrexed (Pem) plus cisplatin (Cis) and concurrent radiotherapy (RT) for 3 cycles, followed by 4 cycles of Pem consolidation, or etoposide plus Cis and concurrent RT for 2 cycles, followed by a consolidation platinum-based doublet regimen for up to 2 cycles. PET scan (yes vs no) was one of the stratification factors since its use was not required per protocol. Subgroup analyses (yes vs no PET) of OS and PFS were conducted on the ITT population regardless of treatment since the study did not demonstrate superior efficacy for either arm. Kaplan-Meier methods and Cox regression models were used to estimate hazard ratios.


Of the 598 patients, the majority (n = 491; 82.1%) had PET scan staging performed. The OS and PFS by PET scan use are presented in the table. In addition, results of subgroup analyses for each treatment arm were consistent with those of the ITT population.

PFS and OS by PET Use

Intent-to-Treat Patients PET Scan
Yes (N = 491) No (N = 107)
Median OS, months 27.2 20.8
95% CI 22.6, 31.0 16.5, 26.3
HR (95% CI) 0.81 (0.62, 1.06)
Log-rank P-value 0.130
Median PFS, months 11.3 9.2
95% CI 9.8, 12.5 8.8, 11.3
HR (95% CI) 0.73 (0.56, 0.93)
Log-rank P-value 0.012

CI, confidence interval; HR, hazard ratio; N, number of patients


Both a significantly improved PFS and a numerically longer OS in the subgroup of patients with PET scans, compared to patients with conventional staging, are consistent with improved survival due to stage migration. The magnitude of differences in OS and PFS based on PET is a reminder of the potential for factors other than the therapeutic intervention to affect outcomes.

Clinical trial identification


Legal entity responsible for the study

Eli Lilly and Company


Eli Lilly and Company


N. Iscoe: Employee of Eli Lilly Canada Inc. R. Govindan: Boehringer Ingelheim, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, Baxalta, Astellas, ARAID Pharmaceuticals. A.M. Hossain: Employed by Eli Lilly and Company. B. San Antonio, N. Chouaki: Employee of Eli Lilly and Company.

E. Vokes: Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Lilly, Genentech, Merck, Synta, VentiRx.

S. Senan: Lilly, Varian Medical Systems. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings